Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based system that utilizes low-dose X-rays for screening of the colon to detect polyps, masses, and colorectal cancers in Israel.
Flawless balance sheet and overvalued.
- Check-Cap is covered by less than 3 analysts.
Share Price & News
How has Check-Cap's share price performed over time and what events caused price changes?
Latest Share Price and Events
7 Day Return
US Medical Equipment
1 Year Return
US Medical Equipment
CHEK underperformed the Medical Equipment industry which returned 9.6% over the past year.
CHEK underperformed the Market in United States of America which returned 2.1% over the past year.
Share holder returns
Price Volatility Vs. Market
How volatile is Check-Cap's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 year ago | Simply Wall StHave Investors Priced In Healthcare Growth For Check-Cap Ltd (NASDAQ:CHEK)?
1 year ago | Simply Wall StBreakeven On The Horizon For Check-Cap Ltd (NASDAQ:CHEK)
1 year ago | Simply Wall StIs There Now An Opportunity In Check-Cap Ltd (NASDAQ:CHEK)?
Is Check-Cap undervalued based on future cash flows and its price relative to the stock market?
Price to Book (PB) ratio
Intrinsic Value Based on Future Cash Flows
Unable to calculate intrinsic value for Check-Cap to establish if it is available at moderate discount.
Unable to calculate intrinsic value for Check-Cap to establish if it is available at substantial discount.
Price Based on Earnings
Check-Cap is loss making, we can't compare its value to the US Medical Equipment industry average.
Check-Cap is loss making, we can't compare the value of its earnings to the United States of America market.
Price Based on Expected Growth
Unable to calculate PEG ratio for Check-Cap, we can't assess if its growth is good value.
Price Based on Value of Assets
Check-Cap is good value based on assets compared to the US Medical Equipment industry average.
How is Check-Cap expected to perform in the next 1 to 3 years based on estimates from 2 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Estimates
Future Annual Growth Analysis
Unable to determine if Check-Cap is high growth as no revenue estimate data is available.
Check-Cap is not considered high growth as it is expected to be loss making for the next 1-3 years.
Unable to compare Check-Cap's revenue growth to the United States of America market average as no estimate data is available.
Unable to compare Check-Cap's earnings growth to the United States of America market average as it is expected to be loss making during the next 1-3 years.
Unable to compare Check-Cap's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Earnings per Share Growth Estimates
Future Return on Equity
Unable to establish if Check-Cap will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
How has Check-Cap performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Past Earnings Growth Analysis
Check-Cap does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
Unable to compare Check-Cap's 1-year earnings growth to the 5-year average as it is not currently profitable.
Unable to compare Check-Cap's 1-year growth to the US Medical Equipment industry average as it is not currently profitable.
Return on Equity
It is difficult to establish if Check-Cap has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
Return on Assets
It is difficult to establish if Check-Cap has efficiently used its assets last year compared to the US Medical Equipment industry average (Return on Assets) as it is loss-making.
Return on Capital Employed
It is difficult to establish if Check-Cap improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
How is Check-Cap's financial position?
Financial Position Analysis
Check-Cap is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Check-Cap's cash and other short term assets cover its long term commitments.
Debt to Equity History and Analysis
Check-Cap has no debt.
Check-Cap has not taken on any debt in the past 5 years.
Low level of unsold assets.
Check-Cap has no debt, it does not need to be covered by short term assets.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Check-Cap has sufficient cash runway for 1.2 years based on current free cash flow.
Check-Cap has sufficient cash runway for 1.1 years if free cash flow continues to grow at historical rates of 9.4% each year.
What is Check-Cap's current dividend yield, its reliability and sustainability?
Dividend Yield and Payments Analysis
Unable to evaluate Check-Cap's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
Unable to evaluate Check-Cap's dividend against the top 25% market benchmark as the company has not reported any payouts.
Unable to perform a dividend volatility check as Check-Cap has not reported any payouts.
Unable to verify if Check-Cap's dividend has been increasing as the company has not reported any payouts.
Current Payout to Shareholders
Unable to calculate sustainability of dividends as Check-Cap has not reported any payouts.
Future Payout to Shareholders
Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
What is the CEO of Check-Cap's salary, the management and board of directors tenure and is there insider trading?
Average management tenure
Alex Ovadia (57yo)
Mr. Alex Ovadia has been Chief Executive Officer of Check-Cap Ltd since February 26, 2018. Mr. Ovadia was Vice President of Research & Development at Check-Cap Ltd. since joining in January 2013. Mr. Ovadi ...
CEO Compensation Analysis
Alex's remuneration is about average for companies of similar size in United States of America.
Alex's compensation has increased whilst company is loss making.
Management Age and Tenure
The average tenure for the Check-Cap management team is less than 2 years, this suggests a new team.
Board Age and Tenure
The tenure for the Check-Cap board of directors is about average.
No 3 month open market individual insider trading information.
Mira Rosenzweig (47yo)
Chief Financial Officer
- Tenure: 0.4yrs
Yoav Kimchy (58yo)
Founder & Chief Technology Officer
- Tenure: 15.4yrs
- Compensation: US$470.29k
Alex Ovadia (57yo)
Chief Executive Officer
- Tenure: 1.6yrs
- Compensation: US$502.91k
Shuki Belkar (50yo)
Vice President of Operations
- Tenure: 0.3yrs
Boaz Shpigelman (48yo)
Vice President of Research & Development
- Tenure: 1.5yrs
- Compensation: US$288.13k
Director of Quality Assurance & Regulatory Affairs
- Tenure: 2yrs
Yuval Yanai (67yo)
- Tenure: 4.5yrs
Walt Robb (91yo)
- Tenure: 10.3yrs
Mary Gorman (59yo)
- Tenure: 4.3yrs
- Tenure: 7.7yrs
Steve Hanley (52yo)
Chairman of the Board
- Tenure: 2yrs
XQ Lin (35yo)
- Tenure: 4.6yrs
- Tenure: 0yrs
Clara Ezed (47yo)
- Tenure: 2.3yrs
Check-Cap Ltd.'s company bio, employee growth, exchange listings and data sources
- Name: Check-Cap Ltd.
- Ticker: CHEK
- Exchange: NasdaqCM
- Founded: 2004
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: US$16.724m
- Shares outstanding: 8.24m
- Website: https://www.check-cap.com
Number of Employees
- Check-Cap Ltd.
- Check-Cap Building
- 29 Abba Hushi Avenue
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|CHEK||NasdaqCM (Nasdaq Capital Market)||Yes||Ordinary Shares||US||USD||Mar 2015|
|7CC||DB (Deutsche Boerse AG)||Yes||Ordinary Shares||DE||EUR||Mar 2015|
Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based system that utilizes low-dose X-rays for screening of the colon to detect polyps, masses, and col ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2019/09/18 01:22|
|End of Day Share Price||2019/09/17 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.